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Abstract
Background: Cardiovascular diseases (CVD) and cancer are worldwide main causes of death with mortality trends
varying across countries with different levels of economic development.
Design and methods: We analysed trends in CVD and cancer mortality for 37 European countries, five high-income
non-European countries and four leading emerging economies (BRICS) using data from the World Health Organization
database for the period 1980–2010.
Results: In high-income countries, CVD mortality trends are characterized by steep declines over the last decades,
while a downward trend in cancer mortality started more recently and was less pronounced. This resulted in the gradual
convergence of the CVD and cancer mortality rates, and the latter are already higher in some countries. The absolute
number of CVD deaths decreased in most settings, while cancer deaths increased in nearly all countries. Among the
BRICS, China and South Africa share a similar pattern of no meaningful variation in both CVD and cancer age-standar-
dized mortality rates and an increase in the overall number of deaths by these causes. Brazil presents trends similar to
those of high-income countries, except for the still increasing number of CVD deaths.
Conclusions: The substantial decreases in CVD mortality over the last decades have overcome the impact of the
growth and ageing of populations in the overall number of deaths, while stabilization in the number of cancer deaths was
observed only in some of the high-income countries.
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Introduction
In high-income countries, cardiovascular diseases
(CVD) are the main cause of death and cancer the
second, while in low- and middle-income countries
these are expected to be the most important determin-
ants of the death toll by 2030.1
In many countries, the age-standardized mortality
rates (ASMR) from CVD have been declining for
four or ﬁve decades, and those of cancer for over two
decades now.2–4 However, the trends are heteroge-
neous, reﬂecting diﬀerences in the importance of
cause-speciﬁc mortality determinants across settings.
The variation in the absolute number of deaths will
also depend on demographic trends, namely regarding
population size and age structure.5
Understanding the variation in CVD and cancer mor-
tality across countries from diﬀerent regions and levels
of economic development is essential to predict the
death burden associated with these major noncommu-
nicable diseases, in particular using high-income coun-
tries, where accurate death certiﬁcation has long been
available, as benchmarks. Therefore, we considered the
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trends in CVD and cancer mortality in 45 countries from
ﬁve continents over the last three decades.
Methods
For the present study, we selected all available
European countries, high-income non-European coun-
tries and also Brazil, India, China, and South Africa.
The latter four, together with the Russian Federation,
are leading emerging economies that have been jointly
referred as BRICS.6 We obtained the CVD and cancer
mortality data (all and selected diseases of the circula-
tory system and cancers, as described in Appendix 1,
available online) from the World Health Organization
(WHO) database (update 24 November 2011)7 for the
period 1980–2010.
India was not considered because there were no data
available on electronic support from the WHO data-
base. Bosnia and Herzegovina, Cyprus, and
Montenegro were excluded because the data available
in the WHO database refers to less than 10 calendar
years. After these exclusions, data was available from
37 European countries, ﬁve high-income non-European
countries (Australia, Canada, Japan, New Zealand,
and USA), and from Brazil, China (including data
from less than 10% of the country population, as well
as data from Hong Kong Special Administrative
Region (SAR)), and South Africa.
Mid-year estimates of the resident population
were obtained from the United Nations, World
Prospects Population, the 2010 revision;6 for China,
population estimates were obtained from WHO data-
base since mortality data refers to <10% of the popu-
lation. Cause- and sex-speciﬁc ASMR were computed
through the direct method, using the World Standard
Population8 as reference. The annual percentage
change (APC) in the ASMR for all CVD and all can-
cers, and the corresponding 95% conﬁdence intervals
(CI), as well as the points in time when trends changed
signiﬁcantly were estimated through joinpoint regres-
sion, using the software Joinpoint 3.5.4.9
Additionally, we computed the cause- and sex-speciﬁc
absolute and relative variation in number of deaths, by
all CVD and all cancers, in the whole period.
We present the results for each country with at least
10 million inhabitants in 2010, as well as for the groups
of high-income non-European and the European
Union (15 member states (EU-15) as deﬁned in
January 1995 and 27 member states (EU-27) as deﬁned
in January 2007).6 The results referring to countries
with less than 10 million inhabitants are also provided
in Appendices 2–6.
To discuss the overall trends in CVD and cancer
mortality, we present graphically the trends in ASMR
and number of deaths for speciﬁc CVD and cancers, in
high-income non-European and EU countries
(Appendices 7 and 8).
Results
ASMR
The CVD ASMR decreased markedly between 1980
and 2010 in most high-income countries, while cancer
ASMR decreased more slowly mainly since the 1990s
(Figures 1 and 2, Tables 1 and 2, and Appendices 2–5).
While in the beginning of the period under analysis
the CVD ASMR were substantially higher in most set-
tings, its declining trends over three decades resulted in
a substantial reduction in the gap between CVD and
cancer rates; in several countries the CVD ASMR are
already lower than the ones observed for cancer, mostly
among men (Figures 1 and 2 and Appendices 2 and 3;
for example France, Japan, The Netherlands, Spain).
Overall, the tendency for lower ASMR for CVD
than for cancer were more pronounced in high-
income non-European countries and in EU-15 than in
EU-27. By the end of the period analysed the latter
presented CVD ASMR approximately 25% higher.
In the Russian Federation, the increasing trends of
CVD ASMR lead to mortality rates 3–4.5-fold higher
than in the more aﬄuent settings, while decreasing
trends were observed since the early 2000s. The
cancer ASMR started to decrease in the early 1990s
and remained much lower than that observed for
CVD. A similar pattern was observed for other
Eastern European countries, namely Belarus,
Republic of Moldova, Ukraine, and Latvia.
In Brazil, a considerable decrease in CVD ASMR
has occurred in the last three decades, while cancer
rates increased signiﬁcantly since the 1990s (APC
0.7%).
In China, the CVD ASMR decreased in both sexes,
though there was no signiﬁcant variation in women
since 1991, while cancer ASMR have been relatively
stable among men and increasing among women since
1996 (APC 1.6%). Speciﬁcally in Hong Kong SAR,
CVD and cancer mortality experienced steep declines,
with cancer ASMR being already higher than that of
CVD.
South Africa had low CVD ASMR with no signiﬁ-
cant variation since the late 1990s, while in the same
period cancer ASMR decreased signiﬁcantly in men
(APC –2.0%).
Absolute number of deaths
The absolute number of CVD deaths decreased in all
high-income non-European countries and most EU
member states. The relative variation in the absolute
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number of CVD deaths among individual countries
ranged between –45.0% and –4.0% in men and between
–41.6% and –5.5% in women (Table 3 and Appendix 6).
Regarding cancer mortality, there was an increase in
the number of deaths in most settings, with relative
variation ranging between –3.6% and 153.1% in men
and between –4.3% and 163.5% in women.
Between 1980 and 2008 the absolute number of
cancer deaths became higher than the number of
CVD deaths in men from France, Hong Kong SAR,
Japan, Netherlands, Slovenia, and Spain. Among
women, the number of CVD deaths is still higher
than for cancer in all countries analysed.
Discussion
In high-income countries, CVD mortality trends are
characterized by steep declines over the last decades,
while a downward trend in cancer mortality started
more recently and was less pronounced. This resulted
in the gradual convergence of the CVD and cancer
mortality rates, and the latter are already higher in
some countries. Among the BRICS, China and South
Africa share a similar pattern of no meaningful vari-
ation in both CVD and cancer ASMR and an increase
in the overall number of deaths by these causes. Brazil
and Hong Kong SAR present trends similar to those of
high-income countries, except for the still increasing
number of CVD deaths.
The present study provides a comprehensive over-
view of the trends in major causes of death worldwide,
but some limitations need to be discussed. Since we are
analysing broad groups of causes of death, mostly in
the more developed areas of the world, diﬀerences in
the quality of coding between countries and over the
years or the use of three diﬀerent revisions of the
International Classiﬁcation of Diseases (ICD) are not
expected to compromise the comparability of data
across countries or over time.10,11 Still, there are
issues of completeness of death certiﬁcation and con-
tent validity that may vary, especially in BRICS and
some of the middle-income countries included in our
analyses. For example, the absence of sustained
health monitoring after the collapse of the Soviet
Union raises concerns regarding data quality in several
Eastern European countries; however, analyses con-
ducted in Russia showed that the exceedingly high
CVD mortality was real and its key determinant was
alcohol abuse.12 In some countries, the mortality rates
may be underestimated and the trends may not apply to
the whole country because data on the number of
deaths is available to less than 90% of the population,
namely Albania (70.8%), Brazil (79.7%), Republic of
Moldova (83.2%), Serbia (83.1%), South Africa
(76.9%), and the Former Yugoslav Republic of
Macedonia (89.2%); however, this is not expected to
meaningfully compromise the comparison of the rates
over time. Such concerns are higher for China, since
mortality data covers less than 10% of the entire popu-
lation and are limited by the use of verbal autopsy
methods in rural areas;13 nevertheless, these are the
best available data for this country, and, as such, still
useful, namely taking into account that these data are
expected to represent the whole country population.14
Our results are in accordance with the 2004 update of
WHO’s The global burden of disease,1 with CVD depict-
ing the highest mortality burden in terms of the absolute
number of deaths, particularly in women, while the rele-
vance of cancer as a leading cause of death is directly
related with socioeconomic status of countries.
Although distinct cardiovascular diseases and can-
cers share some important risk factors, the strength of
the associations and lag-times are diﬀerent; the geo-
graphical distribution and trends of these exposures
are therefore expected to have a diﬀerent impact on
the mortality by CVD or cancer.
Smoking increases the risk of stroke and myocardial
infarction by 2–4-fold, and the trends in CVD ASMR
are closely associated with the variation in the patterns
of smoking.15–17 However, the variation in the patterns
of smoking had also a major contribution to the
declines in cancer ASMR among men, and for the
less favourable trends among women,18 since lung
cancer is one of the most important causes of cancer
death in most developed settings (Appendix 8). In con-
trast, although alcohol consumption is strongly asso-
ciated with upper digestive and respiratory tract
cancers,19 it has a smaller contribution to the overall
cancer mortality than other risk factors.20 Conversely,
alcohol abuse is a major determinant of the CVD
ASMR ﬂuctuations, as already shown in Eastern
European countries.12
The decline in stomach cancer mortality among
high-income countries, largely explained by the reduc-
tion in the prevalence of Helicobacter pylori infection,
and the access to a better diet that accompanied the
general improvement in the populations’ living condi-
tions,21 had an important contribution to overall reduc-
tion in cancer mortality (Appendix 8). Colorectal,
breast, and prostate are the cancer sites responsible
for a larger number of deaths (Appendix 8) and the
recent decline in their ASMR contributes to the overall
reduction in cancer mortality. This probably reﬂects a
more eﬀective control of cancer through the increase in
the proportion of the population covered by eﬀective
screening practices, especially among women,22,23 or
the access to more eﬀective management strategies.24,25
The obesity epidemic26,27 may slow down, or even
reverse, the observed downward trends in the mortality
from colorectal and selected hormone-related cancers,
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Table 3. Sex- and cause-specific number of deaths and respective absolute and relative variation
Country Overall period Cause
Men Women
No. of deaths Variation No. of deaths Variation
Initial Final Absolute (n) Relative (%) Initial Final Absolute (n) Relative (%)
HI non-European 19802004 CVD 730,365 636,921 93,444 12.8 704,131 704,505 374 0.1
Cancer 365,093 536,760 171,668 47.0 295,373 443,310 147,937 50.1
EU-15 19902005 CVD 744,232 627,931 116,301 15.6 893,238 777,397 115,841 13.0
Cancer 505,589 537,106 31,517 6.2 404,965 419,792 14,827 3.7
EU-27 19922005 CVD 1,052,579 920,170 132,409 12.6 1,225,269 1,105,130 120,139 9.8
Cancer 640,717 677,002 36,286 5.7 504,215 525,718 21,503 4.3
Australia 19802006 CVD 29,369 21,727 7642 26.0 27,000 23,881 3119 11.6
Cancer 13,761 21,158 7397 53.7 10,230 16,383 6153 60.1
Belgium 1980–2005 CVD 23,945 15,791 8154 34.1 25,453 19,161 6292 24.7
Cancer 15,468 14,907 561 3.6 11,222 11,122 100 0.9
Brazil 1980–2008 CVD 102,532 162,270 59,738 58.3 88,367 147,109 58,742 66.5
Cancer 33,841 85,639 51,798 153.1 27,807 73,286 45,478 163.5
Canada 1980–2004 CVD 43,714 36,671 7043 16.1 36,504 37,203 700 1.9
Cancer 22,690 34,802 12,112 53.4 17,962 31,262 13,300 74.0
China 19872000 CVD 108,101 140,128 32,027 29.6 104,157 124,346 20,190 19.4
Cancer 71,952 93,085 21,134 29.4 44,272 56,366 12,094 27.3
Hong Kong SAR 1980–2009 CVD 3757 5578 1821 48.5 3641 5311 1671 45.9
Cancer 4080 7600 3520 86.3 2529 4937 2409 95.3
Czech Republic 1986–2009 CVD 33,785 23,716 10,070 29.8 38,326 29,232 9093 23.7
Cancer 15,489 15,337 152 1.0 12,096 12,200 104 0.9
France 1980–2008 CVD 93,130 68,224 24,907 26.7 108,376 77,572 30,803 28.4
Cancer 75,519 88,971 13,452 17.8 50,534 61,227 10,694 21.2
Germany 1990–2010 CVD 188,392 149,419 38,973 20.7 263,610 205,874 57,736 21.9
Cancer 104,974 117,082 12,108 11.5 104,436 99,985 4451 4.3
Greece 1980–2009 CVD 18,603 23,403 4800 25.8 20,036 25,866 5830 29.1
Cancer 10,058 16,633 6575 65.4 6566 10,557 3991 60.8
Italy 1980–2008 CVD 124,112 97,485 26,627 21.5 134,505 125,839 8666 6.4
Cancer 72,892 93,013 20,121 27.6 50,988 70,272 19,284 37.8
Japan 1980–2009 CVD 152,560 158,064 5504 3.6 151,626 172,665 21,039 13.9
Cancer 96,380 205,154 108,775 112.9 69,718 136,029 66,311 95.1
Netherlands 1980–2010 CVD 27,714 18,454 9260 33.4 24,350 20,891 3459 14.2
Cancer 18,441 22,531 4090 22.2 12,918 18,960 6042 46.8
Poland 1980–2009 CVD 81,092 81,975 883 1.1 82,171 92,119 9948 12.1
Cancer 33,887 52,325 18,438 54.4 26,868 40,785 13,916 51.8
Portugal 1980–2009 CVD 19,290 15,043 4247 22.0 21,690 18,803 2887 13.3
Cancer 7899 14,278 6379 80.8 6521 9752 3231 49.6
Romania 1980–2010 CVD 59,750 73,500 13,750 23.0 67,913 81,179 13,265 19.5
Cancer 16,130 27,849 11,719 72.7 12,609 18,981 6372 50.5
Russian Federation 1980–2009 CVD 308,384 527,847 219,463 71.2 493,542 641,428 147,885 30.0
Cancer 118,710 154,398 35,688 30.1 109,876 133,364 23,488 21.4
South Africa 1993–2008 CVD 19,945 37,314 17,369 87.1 20,386 45,374 24,988 122.6
Cancer 12,455 17,052 4597 36.9 10,010 16,580 6570 65.6
Spain 1980–2009 CVD 62,413 55,851 6562 10.5 70,355 66,474 3881 5.5
Cancer 35,175 62,824 27,649 78.6 24,486 38,020 13,533 55.3
UK 1980–2010 CVD 161,427 90,936 70,490 43.7 167,184 97,621 69,563 41.6
Cancer 77,855 81,789 3934 5.1 69,049 74,715 5667 8.2
Ukraine 1981–2009 CVD 134,907 206,317 71,410 52.9 205,565 264,048 58,483 28.4
Cancer 41,257 48,796 7539 18.3 36,911 39,140 2229 6.0
(continued)
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as well as CVD. Speciﬁcally, the mortality for ischemic
heart disease at younger adult ages already started to
increase in some European countries, and this has been
attributed mostly to the eﬀect of increasing prevalence
of obesity and diabetes.28
The decline in CVD mortality observed among high-
income countries has been explained with increased
control of cholesterol levels and hypertension, which
directly aﬀect the incidence of CVD.15–17 Also, evi-
dence-based pharmacological and interventional thera-
pies, such as thrombolysis, percutaneous coronary
angioplasty, statins, and angiotensin-converting
enzyme inhibitors, led to the decline of ischemic heart
disease case-fatality rates, contributing to explain
approximately half of the decline in the disease-speciﬁc
mortality.15–17 The eﬃcacy of acute management and
secondary prevention for stroke is less pronounced and
the proportion of cases covered is in general smaller.29
This could explain the steeper decline in ischemic heart
disease than stroke mortality rates in most settings
(Appendix 7), particularly among men, since for a
long time women have consistently been less aggres-
sively diagnosed and treated.30,31
In conclusion, in a few high-income countries the
ASMR for CVD are currently lower than those for
cancer, and the consistent decreases in CVD mortality
over the last decades have overcome the impact of the
growth and ageing of populations in the overall number
of deaths. On the other hand, stabilization in the abso-
lute number of cancer deaths was observed only in
some of the more aﬄuent countries, reﬂecting more
modest and less generalized declines in the cancer
ASMR, as well as the reduction of the importance of
CVD as a competing risk.
These ﬁndings show that a higher mortality of
cancer than CVD is to be expected in the next decades,
along with an increased burden over the health systems.
This underlines the need to reinforce primary preven-
tion, namely through the control of risk factors such as
smoking or obesity, along with a rational use of early
diagnosis and management strategies proved to be
eﬀective for mortality reduction.
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